NASDAQ:TWST

Twist Bioscience (TWST) Stock Forecast, Price & News

$20.54

+0.67 (+3.37%)

(As of 09/27/2023 ET)

Compare

Today's Range: $20.09
▼
$21.35
50-Day Range: $18.62
▼
$26.57
52-Week Range: $11.46
▼
$40.50

Volume: 1.12 million shs
Average Volume: 1.22 million shs
Market Capitalization: $1.18 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.67

Twist Bioscience MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 38.4% Upside
$28.43 Price Target
Short Interest: Bearish
24.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.42
Upright™ Environmental Score
News Sentiment: 0.76
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.73) to ($3.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

620th out of 976 stocks

Biological Products, Except Diagnostic Industry

94th out of 159 stocks

3.4

Analyst's Opinion

Consensus Rating
Twist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.43, Twist Bioscience has a forecasted upside of 38.4% from its current price of $20.54.
Amount of Analyst Coverage
Twist Bioscience has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
24.36% of the outstanding shares of Twist Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Twist Bioscience has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Twist Bioscience has recently decreased by 1.41%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Twist Bioscience does not currently pay a dividend.
Dividend Growth
Twist Bioscience does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Twist Bioscience has received a 65.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Deoxyribonucleic acid (DNA)" and "Monoclonal antibodies for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Twist Bioscience is -1.42.

2.6

News and Social Media Coverage

News Sentiment
Twist Bioscience has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Twist Bioscience this week, compared to 3 articles on an average week.
Search Interest
17 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Twist Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.80% of the stock of Twist Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Twist Bioscience are expected to grow in the coming year, from ($3.73) to ($3.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Twist Bioscience is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Twist Bioscience is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Twist Bioscience has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Price History

30 days | 90 days | 365 days | Advanced Chart

TWST Stock News Headlines

September 27, 2023 | markets.businessinsider.com

Twist Bioscience Corp., IMIDomics Enter Multi-program Collaboration - Quick Facts

September 26, 2023 | finance.yahoo.com

Twist Bioscience (TWST) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards

September 27, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

August 31, 2023 | finance.yahoo.com

Should You Add Twist Bioscience Corporation (TWST) to Your Portfolio?

August 24, 2023 | msn.com

Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand

August 7, 2023 | finance.yahoo.com

Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023

August 6, 2023 | markets.businessinsider.com

Barclays Sticks to Its Buy Rating for Twist Bioscience (TWST)

August 6, 2023 | seekingalpha.com

Twist Bioscience: Evaluating Its Conglomerate Of Innovation, Growth, And Vulnerabilities

September 27, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

August 5, 2023 | marketwatch.com

Twist Bioscience Shares Jump 14% on 3Q Loss, Revenue Beat

August 5, 2023 | markets.businessinsider.com

Twist Bioscience Corp Q3 Loss decreases, beats estimates

August 5, 2023 | finance.yahoo.com

Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results

August 5, 2023 | markets.businessinsider.com

Twist Bioscience Stock Soars After Q3 Report - Here's Why

August 4, 2023 | seekingalpha.com

Twist Bioscience Corporation 2023 Q3 - Results - Earnings Call Presentation

August 3, 2023 | benzinga.com

Twist Bioscience's Earnings Outlook

July 29, 2023 | finanznachrichten.de

Twist Bioscience Corporation: Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research

July 18, 2023 | finance.yahoo.com

Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research

June 26, 2023 | finance.yahoo.com

Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism

June 16, 2023 | bizjournals.com

Synthetic biology pioneer Twist to cut 212 jobs

May 31, 2023 | finanznachrichten.de

Twist Bioscience Corporation: Twist Bioscience to Present at ITF World 2023

May 24, 2023 | seekingalpha.com

Twist Bioscience: Progress On Margins Could Put A Floor Under The Stock

May 19, 2023 | seekingalpha.com

Reconsidering Twist Biosciences

May 8, 2023 | msn.com

Barclays Maintains Twist Bioscience (TWST) Overweight Recommendation

May 8, 2023 | markets.businessinsider.com

Analyst Ratings for Twist Bioscience

May 7, 2023 | finance.yahoo.com

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Call Transcript

May 5, 2023 | bizjournals.com

Despite record quarterly revenue, Twist Bioscience to cut 25% of workforce

May 5, 2023 | msn.com

Recap: Twist Bioscience Q2 Earnings

See More Headlines

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Company Calendar

Last Earnings: 8/04/2023
Today: 9/27/2023
Fiscal Year End: 9/30/2023
Next Earnings (Estimated): 11/17/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TWST
CUSIP: N/A
CIK: 1581280
Web: www.twistbioscience.com
Phone: (800) 719-0671
Fax: N/A
Employees: 989
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.43
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +41.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-217,860,000.00
Net Margins: -88.97%
Pretax Margin: -88.26%
Return on Equity: -29.09%
Return on Assets: -23.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.12
Quick Ratio: 5.62

Sales & Book Value

Annual Sales: $203.57 million
Price / Sales: 5.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.01 per share
Price / Book: 1.45

Miscellaneous

Outstanding Shares: 57,400,000
Free Float: 50,623,000
Market Cap: $1.16 billion
Optionable: Not Optionable
Beta: 1.28

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Emily Marine Leproust Ph.D. (Age 49)
Co-Founder, Chairman & CEO
Comp: $1.4M

Dr. Patrick John Finn Ph.D. (Age 51)
Pres & COO
Comp: $801.78k

Mr. James M. Thorburn (Age 67)
CFO & Principal Accounting Officer
Comp: $815.16k

Mr. Dennis Cho (Age 52)
Sr. VP, Gen. Counsel, Sec. and Chief Ethics & Compliance Officer
Comp: $537.93k

Dr. William Charles Banyai Ph.D. (Age 68)
Sr. VP of Advanced Devel., GM of Data Storage & Director
Comp: $745.64k

Mr. Robert F. Werner (Age 50)
Chief Accounting Officer

Mr. Siyuan Chen
Chief Technology Officer

Dr. Aaron K. Sato Ph.D.
Chief Scientific Officer

Mr. Chet Gandhi
Chief Information Officer

Ms. Paula Green (Age 55)
Sr. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.
What is Twist Bioscience's stock price forecast for 2023?: 7 brokers have issued 1 year price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $20.00 to $36.00. On average, they expect the company's stock price to reach $28.43 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.
How have TWST shares performed in 2023?: Twist Bioscience's stock was trading at $23.81 at the start of the year. Since then, TWST shares have decreased by 14.8% and is now trading at $20.28.
View the best growth stocks for 2023 here.
When is Twist Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 17th 2023.
View our TWST earnings forecast.
How were Twist Bioscience's earnings last quarter?: Twist Bioscience Co. (NASDAQ:TWST) posted its quarterly earnings data on Friday, August, 4th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. The firm had revenue of $63.80 million for the quarter, compared to analyst estimates of $60.62 million. Twist Bioscience had a negative net margin of 88.97% and a negative trailing twelve-month return on equity of 29.09%. Twist Bioscience's revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period last year, the business posted ($1.08) earnings per share.
What ETFs hold Twist Bioscience's stock?: ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include Subversive Mental Health ETF (SANE), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), WisdomTree BioRevolution Fund (WDNA), BNY Mellon Innovators ETF (BKIV) and SPDR S&P Biotech ETF (XBI).
What guidance has Twist Bioscience issued on next quarter's earnings?: Twist Bioscience updated its fourth quarter 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$64.00 million, compared to the consensus revenue estimate of $62.25 million.
What is Emily Leproust's approval rating as Twist Bioscience's CEO?: 44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).
When did Twist Bioscience IPO?: (TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.
What is Twist Bioscience's stock symbol?: Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."
Who are Twist Bioscience's major shareholders?: Twist Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.18%), BlackRock Inc. (12.03%), JPMorgan Chase & Co. (8.95%), State Street Corp (8.45%), William Blair Investment Management LLC (6.30%) and Sumitomo Mitsui Trust Holdings Inc. (6.24%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends.
How do I buy shares of Twist Bioscience?: Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Twist Bioscience's stock price today?: One share of TWST stock can currently be purchased for approximately $20.28.
How much money does Twist Bioscience make?: Twist Bioscience (NASDAQ:TWST) has a market capitalization of $1.16 billion and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.
How many employees does Twist Bioscience have?: The company employs 989 workers across the globe.
How can I contact Twist Bioscience?: Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial